Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
Rheumatol Int
; 38(5): 879-885, 2018 May.
Article
en En
| MEDLINE
| ID: mdl-29450637
ABSTRACT
Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5-10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fiebre Mediterránea Familiar
/
Factores Inmunológicos
/
Anticuerpos Monoclonales
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Humans
País como asunto:
Asia
Idioma:
En
Año:
2018
Tipo del documento:
Article